Takayasu Arteritis Clinical Trials and Treatments

Takayasu Arteritis is a chronic, granulomatous inflammatory disease of large elastic arteries, particularly the aorta and its proximal branches. The pathophysiology involves T cell-mediated inflammatory infiltration of the vessel wall, leading to intimal thickening, medial hypertrophy, fibrosis, and vascular remodeling. The disease progresses through an active inflammatory phase followed by a fibrotic phase characterized by stenosis, dilation, and aneurysm formation.

The most common symptoms of Takayasu Arteritis include Fatigue, malaise, and fever (in active phases), Limb claudication (pain with activity) from arterial narrowing, Headaches and visual disturbances from carotid involvement, Chest or back pain from aortic involvement, Hypertension from renal artery involvement, among others. About 1 new case per million people each year, according to a 2021 review that pooled studies from several countries (1.11 per million person-years), and about 2 per million a year among women. Rates vary between populations, and the disease appears most common in Asia, where few incidence studies have been done. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Takayasu Arteritis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. No medicine has an FDA label for Takayasu arteritis. Doctors use glucocorticoids and other immune-suppressing medicines off-label, and the 2021 American College of Rheumatology and Vasculitis Foundation guideline covers how to choose among them, including TNF inhibitors and tocilizumab.

As of October 21, 2026, no current FDA drug label names Takayasu Arteritis as a condition the drug treats.

The exact cause of Takayasu Arteritis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Cause unknown; HLA associations (HLA-B52 in Asian populations) only shift risk and no diagnostic gene test exists. About 1 new case per million people each year, according to a 2021 review that pooled studies from several countries (1.11 per million person-years), and about 2 per million a year among women. Rates vary between populations, and the disease appears most common in Asia, where few incidence studies have been done. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Takayasu Arteritis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Cause unknown; HLA associations (HLA-B52 in Asian populations) only shift risk and no diagnostic gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Takayasu Arteritis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Takayasu Arteritis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.